Significance of Image Guidance to Clinical Outcomes for Localized Prostate Cancer

Table 1

Patient characteristic.

Patient demographics	IG-IMRT; (𝑛=65)		IMRT; (𝑛=62)		𝑃 value
	𝑛	%	𝑛	%
Preradiotherapy PSA
<10	58	89.23	49	79.03	0.286
10–20	4	6.15	7	11.29
>20	3	4.62	6	9.68
Total Gleason score
<7	10	15.38	12	19.35	0.559
7	20	30.77	23	37.10
>7	34	52.31	27	43.55
T stage
T1	0	0	2	3.22	0.529
T2	30	46.15	27	43.55
T3	35	53.85	33	53.23
Age (y)
<70	14	21.54	18	29.03	0.331
≥70	51	78.46	44	70.97
NCCN risk
Low	2	3.08	2	3.23	0.933
Intermediate	13	20.00	10	16.13
High	50	76.92	50	80.64
Neoadjuvant ADT
Yes	56	86.15	52	83.87	0.718
No	9	13.85	10	16.13

ADT: androgen deprivation therapy; NCCN: National Comprehensive Cancer Network; PSA: prostate-specific antigen.